In one embodiment, methods for detecting a specific nucleic acid sequence in a genome are provided that may include: a) inducing a nick in genomic nucleic acid sequences by a gene editing complex; b) denaturing the genomic nucleic acid sequences by contacting the genomic nucleic acid sequences with a helicase enzyme at the nicked genomic nucleic acid sequences; c) contacting the denatured genome with a detectably labeled probe, wherein the detectably labeled probe is complementary to the specific nucleic acid sequence of interest; and, d) detecting the specific nucleic acid sequence of interest.
C12Q 1/6827 - Hybridisation assays for detection of mutation or polymorphism
C12N 15/11 - DNA or RNA fragmentsModified forms thereof
C12Q 1/34 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving hydrolase
C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
C12Q 1/6816 - Hybridisation assays characterised by the detection means
2.
QUANTIFICATION OF LIGAND BIAS AND MUTATION-INDUCED SIGNALING BIAS IN EGFR PHOSPHORYLATION IN DIRECT RESPONSE TO LIGAND BINDING
The present disclosures relate to novel methods for detecting and quantifying receptor tyrosine kinase phosphorylation in the absence of cytoplasmic molecules and without contributions from feedback loops and system bias; novel methods for screening for a ligand that induces preferential phosphorylation of a tyrosine residue on a receptor tyrosine kinase; novel methods for identifying a signaling bias induced by the receptor tyrosine kinase mutation; novel method for quantifying receptor tyrosine kinase phosphorylation upon ligand stimulation The methods can be used to determine a new intrinsic ligand bias, a new mutation-induced bias coefficient, and a transducer function describing RTK phosphorylation upon ligand stimulation. These critical descriptors of RTK activation are measured in direct response of the RTKs to ligand binding, without contributions from downstream signaling feedback loops and system bias.
A dendrimer-hyaluronic acid hydrogel including a methacrylate-functionalized hyaluronic acid ("HA") and a methacrylate-functionalized hydroxyl dendrimer [poly(amidoamine) can be easily applied over or into a corneal wound or a partially removed cornea to form new corneal tissue. The HA crosslinked hydrogel slowly degrades and facilitates regeneration of the cornea over a 6–10-month period, resulting in a tissue structure with structural and functional elements of the original cornea. The HA promotes corneal tissue regeneration, while the dendrimer component allows the ideal modulus within the hydrogel network, preserving corneal surface integrity.
A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
A61L 24/00 - Surgical adhesives or cementsAdhesives for colostomy devices
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61L 15/00 - Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
4.
NOVEL PHARMACOLOGICAL MECHANISM TO BLOCK STRESS-INDUCED CORTISOL PRODUCTION
Methods for reducing stress-induced hormone production and treating a disease, disorder, or condition associated with an increase in stress-induced hormones by administering a therapeutically effective amount of a glutamate carboxypeptidase II (GCPII) inhibitor to a subject in need of treatment are disclosed.
G01N 33/74 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving hormones
A61P 5/46 - Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
5.
PRIDOPIDINE AND SIGMA 2 ANTAGONIST AGENT FOR TREATING HUNTINGTON DISEASE AND SYMPTOMS THEREOF
Provided herein a method for treatment, prevention, alleviation, delaying symptom onset, or slowing of progression of Huntington disease, comprising administering a composition comprising pridopidine or pharmaceutically acceptable salt thereof and at least one composition comprising sigma 2 antagonist agent.
A61K 31/451 - Non-condensed piperidines, e.g. piperocaine having a carbocyclic ring directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
A61P 25/14 - Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 31/403 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61K 31/46 - 8-Azabicyclo [3.2.1] octaneDerivatives thereof, e.g. atropine, cocaine
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/135 - Amines, e.g. amantadine having aromatic rings, e.g. methadone
A61K 31/472 - Non-condensed isoquinolines, e.g. papaverine
The present invention relates to a solid composition comprising microparticles of a diarylquinoline, such as TBAJ-876, dispersed within a matrix comprising one or more excipients, the one or more excipients selected from: docusate sodium (AOT), hydroxypropylmethyl cellulose (HPMC), lactose, mannitol, polyethylene glycol (PEG), poloxomers, polyoxyethylene (80) sorbitan monooleate, polyvinyl alcohol (PVA), polyvinyl alcohol-polyethylene glycol (PVA-PEG) graft copolymers, polyvinylpyrrolidones (PVP), sodium deoxycholate (NDC), sucrose, and combinations thereof.
The present disclosure relates to the field of proteomics. More specifically, the present disclosure provides compositions and methods for molecular indexing of proteins by self-assembly. In one aspect, the present disclosure provides a library of self-assembled protein-DNA conjugates. In particular embodiments, each protein-DNA conjugate comprises (a) a cDNA comprising a barcode, wherein the cDNA is conjugated with a ligand that specifically binds a polypeptide tag; and (b) a fusion protein comprising the polypeptide tag and a protein of interest, wherein the ligand is covalently bound to the polypeptide tag.
in vitroin vivoin vivo. These can be administered topically, as to the eye, in nano or microsuspensions in sterile saline, as a powder, or as an injectable for local tissue treatment.
A molecular sensing device and molecular sensing method that are based on quantum plexcitonic states on strongly coupled nanophotonic systems are disclosed. The molecular sensing device includes a metasurface, a layer of a semiconducting and/or dielectric material disposed onto a layer of electrically conducting material, a metal nanohole array disposed onto the metasurface, a biological recognition element disposed onto a surface of the metal nanohole array, and where the surface of the metal nanohole array is configured to receive a bioanalyte and a plurality of quantum emitters. The molecular sensing device can be a mixture of quantum emitters, comprising gold, having more than one aspect ratio. The molecular sensing device may include a spectroscopic instrument, including a portable detector. The one or more biological recognition elements are configured to recognize a communicable disease in response to the presence of a specific biological recognition element.
Methods for early detection of certain diseases, including eurodegenerative disease, chronic inflammation, Liver Cirrhosis and non-neoplastic dysregulation of cellular growth are provided. These methods utilize cell free DNA (cfDNA) fragmentomes as biomarkers that distinguish specific diseases.
G16B 30/00 - ICT specially adapted for sequence analysis involving nucleotides or amino acids
G16B 40/00 - ICT specially adapted for biostatisticsICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
C12Q 1/6874 - Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation [SBH]
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
C12Q 1/6809 - Methods for determination or identification of nucleic acids involving differential detection
C12Q 1/6876 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
The present disclosure relates to negative-carbon cement (NC2) production, which can be achieved by integrating carbon dioxide hydrogenation and methane pyrolysis into the cement manufacturing process, using hydrogen gas derived from methane pyrolysis as the fuel for heating, and converting any captured carbon dioxide into solid carbon. The solid carbon can be incorporated into building materials such as portland cement and gypsum boards, fixing the carbon to achieve cradle-to-gate emission reduction.
B01J 8/02 - Chemical or physical processes in general, conducted in the presence of fluids and solid particlesApparatus for such processes with stationary particles, e.g. in fixed beds
C04B 2/10 - Preheating, burning, calcining or cooling
A linear bearing clutch toggle includes a first surface, a second surface, one or more contact elements, a holding device, and a toggle device. The first surface includes a tapered surface. The second surface includes a flat or curved surface. The holding device is configured to hold the one or more contact elements. The toggle device is configured to engage the one or more contact elements with the first surface in a first configuration and to disengage the one or more contact elements from the first surface in a second configuration. The toggle device is configured to permit unidirectional motion along the second surface in the first configuration and to permit bidirectional motion along the second surface in the second configuration.
F16D 41/061 - Freewheels or freewheel clutches with intermediate wedging coupling members between an inner and an outer surface the intermediate members wedging by movement having an axial component
A base station information-based vendor classification process includes extracting, decoding, and grouping the base station information. The grouped base station information is a list associated with types of cellular network technology that is filtered based on the types used by the transmitters. The filtered list is converted to vectors of feature/value pairs, encoded, and provided to a pre-trained classifier. The classifier provides a classification confidence for base station vendors, and an action can be taken based on a comparison between the classification confidence and a list of allowed vendors.
Provided herein are, inter alia, methods, compositions and kits for treating or preventing coronaviruses, e.g., SARS-CoV-2. Also included herein are kits for treating or preventing coronaviruses, e.g., SARS-CoV-2.
The present disclosure relates to methods of identifying a subject with high or low Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), wherein the subject is known to have Systemic Lupus Erythematosus (SLE), and wherein a subject with a high SLEDAI can be treated and a subject with a low SLEDAI can reduce treatment relative to that before the low SLEDAI determination. The methods herein involve detecting the presence of an antibody binding at least one biomarker selected from Ro52Ex4, Ro52Ex3-4, Ro52γCT, and/or Ro52Nt in a sample using routine techniques known in the art.
The present invention relates to a chimeric extracellular vesicle including a stem cell derived extracellular vesicle (SC-EV) and a liposome containing a therapeutic agent. The SC-EV, derived from stem cells, provides a carrier for the delivery of therapeutic agents. The liposome encapsulates a therapeutic agent, ensuring its stability and controlled release. The combination of SC-EV and liposome allows for targeted and efficient delivery of the therapeutic and imaging agents to specific cells or tissues, enhancing its therapeutic efficacy.
Provided herein are methods of measuring effects of immune suppression in a subject, the method comprising (a) quantifying a number of immune cells in a biological sample of the subject: (b) determining an expression level of a protein from the biological sample; and (c) analyzing the number of immune cells and the expression level of the protein, thereby measuring the effects of immune suppression in the subject.
Provided herein are methods of functionalizing C(sp3)-H bonds using reprogramed metalloenzymes to perform radical-relay C(sp3)-H functionalization, activating a (sp3)-H bond via a reactive radical (X·) via hydrogen atom transfer (HAT); intercepting of the resulting carbon-centered radical by a redox-reactive metal complex; and obtaining a functionalized C—Y bond.
The present disclosure provides nucleic acids, compositions, and methods of preventing or treating neurodegenerative disease in a subject comprising administering to the subject an agent that targets CHMP2B. In some embodiments the present disclosure provides a method of preventing or decreasing nuclear accumulation of CHMP7 in a cell comprising contacting the cell with an agent that targets expression of CHMP2B in the cell.
This document describes methods and materials for treating cancer. In some cases, one or more diterpenoid epoxide compounds can be administered to a mammal (e.g., a human) having cancer to treat that mammal. For example, one or more diterpenoid epoxide compounds and one or more inhibitors (e.g., nucleoside-analog inhibitors) of a nucleoside DNA methyltransferase (DNMT) polypeptide can be administered to a mammal (e.g., a human) having cancer to treat that mammal.
Hybrid nanoparticles having a defined size in a range between about 50 nm to about 1000 nm prepared by a kinetic assembly process are disclosed. The hybrid nanoparticles comprise a biodegradable polycation and a PEGylated lipid and include a nucleic acid including, but not limited to, plasmid DNA, messenger RNA (mRNA), small interfering RNA (siRNA), and the like. The assembled hybrid nanoparticles can be used for gene delivery therapy in vivo through various delivery routes and ex vivo and in vitro to transfect cells of interest. The disclosed hybrid nanoparticles with certain sizes within a sub-micron range exhibited significantly improved transfection efficiency compared to nanoparticles without size control.
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
22.
COMPOSITIONS OF AN ARTIFICIAL LYMPH NODE MATRIX AND METHODS OF PREPARING THE SAME
Disclosed are an artificial lymph node (aLN) comprising an extracellular matrix (ECM) hydrogel conjugated with an antigen presenting complex (Signal 1), a co-stimulatory ligand (Signal 2), and T cell-stimulating cytokine (Signal 3) and methods of their use for stimulating one or more T cells and treating a disease, disorder, or condition selected from a cancer, an infectious disease, and an autoimmune disease.
Systems and methods for imaging vertebrae are disclosed. The systems and methods can include awearable ultrasound device with a transducer, the wearable ultrasound device configured to generate vertebrae imaging data when situated to a side of the vertebrae, where the generated vertebrae imaging data is acquired based on translational scans of the imaged vertebrae by the transducer and based on rotational scans of the imaged vertebrae by the transducer. In a further aspect, the systems and methods can include an image reconstruction module configured to process the vertebrae imaging data based, at least in part, the vertebrae imaging data acquired from redundant insonification angles.
4222 to CO offers a sustainable and potentially cost-effective way to produce these products. Further, the production of CO can be used as a means of storing renewable energy. By converting excess renewable energy into CO, it can be stored and transported easily, and when needed, it can be converted back into energy in the form of electricity or fuels.
C25B 11/091 - Electrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of at least one catalytic element and at least one catalytic compoundElectrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of two or more catalytic elements or catalytic compounds
The present invention relates to novel compositions and methods to produce 3D organ equivalents of the brain (i.e. “mini-brains”). The invention also relates to methods of using human induced pluripotent stem cells, a combination of growth and other soluble factors and gyratory shaking. Cells from healthy or diseased donors or animals can be used to allow testing different genetic backgrounds. The model can be further enhanced by using genetically modified cells, adding micro-glia or their precursors or indicator cells (e.g. with reporter genes or tracers) as well as adding endothelial cells to form a blood-brain-barrier.
A sensor device, according to the present invention, is designed to detect an intravenous therapy (IV) infiltration. The device includes a pressure and/or force sensor placed in between two pressure sensitive adhesive tapes. The sensor is then applied over the IV site to detect IV infiltration. During an IV infiltration, the pressure sensitive adhesive tape will experience force, stretch and/or deform. Stretching is registered as an increase in resistance, because the individual units are spread apart, and electrical continuity is lowered. When the sensor detects a change in resistance, the sensor triggers an alert to a health care provider to check the patient's IV.
Fluorescent imaging systems for performing an endoscopic procedure, such as a retrograde cholangiopancreatography (ERCP) procedure may include a first light source for emitting light in the visible spectrum, or light in the near infrared (NIR) spectrum, or both. A light source bandpass filter may block the emitted light in the visible spectrum, or in the NIR spectrum, or both. A first sensor may be capable of detecting the light in the visible spectrum, or the light in the NIR spectrum, or both. A sensor bandpass filter may block the detected light in the visible spectrum, or in the NIR spectrum, or both. The first or a second light source, or the first or a second sensor, or combinations thereof, may be removably disposed on a duodenoscope.
A61B 1/04 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor combined with photographic or television appliances
A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor
A61B 1/018 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor characterised by internal passages or accessories therefor for receiving instruments
A61B 1/05 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor combined with photographic or television appliances characterised by the image sensor, e.g. camera, being in the distal end portion
A61B 1/06 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor with illuminating arrangements
A61B 1/07 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor with illuminating arrangements using light-conductive means, e.g. optical fibres
A61B 1/273 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor for the upper alimentary canal, e.g. oesophagoscopes, gastroscopes
Compositions in the prevention and treatment of cancers, such as colorectal cancer or diseases associated with abnormal levels of β-1,4-galactosyltransferase-V (β-1,4-GalT-V), include at least one inhibitor of glycosphingolipid synthesis.
A system and method for precise spatial patterning of the liquid crystal (LC) director through a two-step photo-exposure process that combines the effects of polarized and unpolarized light. The system and method allow for the simultaneous control of both the polar (out-of-plane) and azimuthal (in-plane) orientations of the LC director, a unit-vector that delineates the local orientational alignment of LC molecules, the mesogens. Embodiments in accordance with the present disclosure provide control over the polar azimuthal orientations of the LC director, enabling tunability of intricate and diverse LC- based photonic devices.
G02F 1/13 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulatingNon-linear optics for the control of the intensity, phase, polarisation or colour based on liquid crystals, e.g. single liquid crystal display cells
C08L 79/08 - PolyimidesPolyester-imidesPolyamide-imidesPolyamide acids or similar polyimide precursors
C09K 19/52 - Liquid crystal materials characterised by components which are not liquid crystals, e.g. additives
H05K 13/00 - Apparatus or processes specially adapted for manufacturing or adjusting assemblages of electric components
30.
AUTOMATIC CALIBRATION FOR RADIOLOGICAL TOMOGRAPHIC IMAGING USING FIDUCIALS WITH UNKNOWN PLACEMENT
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (USA)
Inventor
Stayman, Joseph Webster
Gang, Jianan Grace
Ma, Yiqun
Abstract
Techniques for radiological tomographic imaging using a first target, where the first target is three dimensional, and where a plurality of fiducials are positioned relative to the first target, are presented. The techniques include: obtaining an initial fiducial localization of at least some of the plurality of fiducials using a radiological imaging machine; labeling, based on the initial fiducial localization, fiducial coordinates of at least some of the plurality of fiducials, where the labeling is based on a plurality of long traces; refining the fiducial coordinates based on the labeling the fiducial coordinates; determining, based on the fiducial coordinates, a geometry of the radiological imaging machine; and acquiring, using the radiological imaging machine and based on the geometry of the radiological imaging machine, a tomographic image of a second target.
Vectors or nucleic acid compositions encoding polypeptides of albumin fused to Flt3L, induce circulating dendritic cells and generate an anti-tumor response. In preferred aspects, the compositions are delivered via electroporation and possess more persistent bioactivity in targeted organs.
The disclosed in vitro systems allow for multiple organs (organoids) to be cultured in the same conditions, connected with the same microcirculation, subjected to the same pathological state, and treated with the same therapeutic approach. This allows for determination of the how various organ systems respond to a pathological stress and also how a therapeutic approach may effect various organoids differently. The in vitro systems also provide for single organoids.
A method, a system, and a non-transitory computer-readable medium provides an interactive patient-level data visualization and analysis tool that illustrates a patient's health trajectory across multiple organ systems. Data from an electronic medical record system and one or more research databases are integrated into an analytics platform. A visualization tool plots the patient's health trajectory and overlays data from an entire user-defined disease cohort as a reference group to visualize a disease course of the patient compared to courses of other patients, with a same disease, selected by a user.
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
34.
PARTICLE CHARACTERISTIC DETERMINATION SYSTEM AND METHOD
A system for particle characteristic determination comprising a sample providing unit, configured to provide a sample comprising a plurality of particles, an obtaining unit, configured to obtain a light spectra data comprising light spectra of the sample, a data processing unit comprising a data compression unit and a particle characteristic determination unit, wherein the data compression unit is configured to compress the light spectra data using a predetermined Nyström extension in a diffusion maps algorithm configured to provide diffusion map coordinates, wherein the particle characteristic determination unit is configured to receive the diffusion map coordinates as input and to determine one or more characteristics of the particles comprised in the sample with one or more non-linear machine learning methods by using the diffusion map coordinates in at least one of the one or more non-linear machine learning methods as input and providing the one or more particle characteristics as output.
B01D 61/48 - Apparatus therefor having one or more compartments filled with ion-exchange material
B01J 47/08 - Column or bed processes during which the ion-exchange material is subjected to a physical treatment, e.g. heat, electric current, irradiation or vibration subjected to a direct electric current
36.
COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING CANCER
Provided herein are compositions and methods for treating cancer. In particular, provided herein are compositions, methods, and uses of increasing the level of glucose-6-phospate (G6PC) (e.g., by administering G6PC polypeptides) for treating cancer.
Techniques for predicting an epileptogenic zone resection surgery outcome for an epilepsy patient are presented. The techniques may include: receiving an identification of a brain location; obtaining a patient brain imaging signal, where the patient brain imaging signal represents interictal activity of the patient's brain; fitting a first dynamical network model to the patient brain imaging signal; calculating a first sink index from the first dynamical network model; constructing, using the first dynamical network model, a synthetic brain imaging signal, where the synthetic brain imaging signal corresponds to a resection at the brain location; fitting a second dynamical network model to the synthetic brain imaging signal; calculating a second sink index from the second dynamical network model; and providing, based on the first sink index distribution and the second sink index distribution, an outcome prediction for resecting the patient's brain at the brain location.
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
A61B 5/24 - Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
A61B 5/291 - Bioelectric electrodes therefor specially adapted for particular uses for electroencephalography [EEG]
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G06N 3/00 - Computing arrangements based on biological models
G16H 20/40 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
38.
MULTIVALENT DENDRIMER CONJUGATED PROTACS FOR CELL-TARGETED TARGETED PROTEIN DEGRADATION
Conjugates containing hydroxylated polyamidoamines (hydroxyl PAMAMs) or a dendrimer formed of a sugar such as a glucose dendrimer and (i) elements of PROTAC or (ii) PROTACs,have been developed, which increase the efficacy of the PROTAC technology by increasing selective delivery to, and uptake at, sites of inflammation such as in the brain. The conjugates can be used for targeted intracellular delivery to degrade misfolded proteins and/or disease-associated proteins located in the cytosol, such that the conjugates can take advantage of a cell's intracellular protein degradation machinery.
A61K 47/59 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
39.
DENDRIMER CONJUGATE COMPOSITIONS FOR INTRACELLULAR DELIVERY OF ANTIBODIES AND ANTIBODY FRAGMENTS
Dendrimer compositions and methods thereof for intracellular delivery of antibodies and antibody fragments are described for treatment of ocular diseases, inflammatory disorders, and neurological disorders
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 47/59 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
40.
Treatment Of Uterine Fibroids Using Purified Collagenase
Disclosed herein are compositions and methods for treating uterine fibroids in vivo, and methods of reducing symptoms associated with uterine fibroids, including pain, bleeding and infertility. The disclosed compositions comprise collagenase in an amount effective to cause shrinkage and/or reduce stiffness of uterine fibroids.
Imaging and radiotherapeutics agents targeting fibroblast-activation protein-α (FAP-α) and their use in imaging and treating FAP-α related diseases and disorders are disclosed.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A device may obtain imaging data. The imaging data that is obtained depicts one or more body parts of a patient. A voltage sensitive dye may be applied to stain nerve tissue associated with the one or more body parts of the patient. The voltage sensitive dye may be activated by neuromodulation applied to stimulate the nerve tissue. The imaging data may capture a fluorescence of the nerve tissue based on the voltage sensitive dye being activated by neuromodulation. The device may provide the imaging data for display.
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
43.
INTRAOPERATIVE MONITOR OF AGGREGATE ORGAN INJURY TIME
A computer system and a computer readable medium are disclosed that are configured to perform and store a computer-implemented method for reducing acute kidney injury during cardiac surgery. The method includes measuring and recording mean arterial pressure (MAP) and central venous pressure (CVP); storing the MAP and CVP data as a raw data series; preprocessing the raw data series as preprocessed data, the preprocessing including one or more of managing artifacts, outliers and missing data; assessing the preprocessed data using a first pressure window across a MAP data range and a second pressure window across a CVP data range; simultaneously tracking a number of minutes within each MAP data range window and within each CVP data range window; determining an outcome of the cardiac surgery; and processing a number of minutes within MAP windows, CVP windows for outcomes to reduce kidney injury.
A sutureless device and methods for deployment of a procedural drain are provided. The sutureless device may comprise an internal component configured to be inserted within an opening in skin of a patient, comprising an internal holding mechanism and an opening configured to receive a procedural drain. The sutureless device may comprise an external component configured to be secured to the internal component, comprising an external holding mechanism and an opening configured to receive the procedural drain. The sutureless device may comprise a securing mechanism configured to secure the internal component to the external component. The internal holding mechanism and the external holding mechanism may be configured to securing a position of the sutureless device within the opening in the skin of the patient. The internal component and the external component may be configured to secure the procedural drain within the opening of the internal component and the opening of the external component.
A61M 25/04 - Holding devices, e.g. on the body in the body, e.g. expansible
A61M 27/00 - Drainage appliances for wounds, or the like
A61M 1/00 - Suction or pumping devices for medical purposesDevices for carrying-off, for treatment of, or for carrying-over, body-liquidsDrainage systems
46.
SYSTEM AND METHOD FOR ULTRAHIGH TEMPERATURE TESTING OF A PHYSICAL PROPERTY OF A SAMPLE
A method of testing a physical property' of a sample includes providing the sample, the sample having an axial dimension that is greater than two orthogonal cross dimensions thereof; attaching first and second interconnects at opposing axial ends of the sample; connecting at least one electrical circuit to the first and second interconnects; passing at least one current through at least the first and second interconnects to provide Joule heating of the first and second interconnects; and performing a test of the physical property of the sample. The first and second interconnects are in thermal connection with the sample to thereby heat the sample at least partially by conductive heating with the first and second interconnects.
G01N 27/14 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance by investigating resistance of an electrically-heated body in dependence upon change of temperature
G01N 25/18 - Investigating or analysing materials by the use of thermal means by investigating thermal conductivity
G01N 25/20 - Investigating or analysing materials by the use of thermal means by investigating the development of heat, i.e. calorimetry, e.g. by measuring specific heat, by measuring thermal conductivity
G01N 3/02 - Investigating strength properties of solid materials by application of mechanical stress Details
G01K 13/00 - Thermometers specially adapted for specific purposes
Techniques for detecting that a radiotherapy prescription is anomalous are presented. The techniques include accessing historical patient data for historical patients, each including a historical radiotherapy prescription and a historical set of diagnostic features; determining a first measure or a second measure, where the first measure includes a distance between the radiotherapy prescription represented as a point in a first multidimensional space and a historical radiotherapy prescription represented as a point in the first multidimensional space, and where the second measure includes a distance between a set of diagnostic features of the patient represented as a point in a second multidimensional space and a historical set of diagnostic features, for a historical patient with a similar historical radiotherapy prescription, represented as a point in the second multidimensional space; detecting the first measure exceeding a first threshold or the second measure exceeding a second threshold; and issuing an alert.
G16H 20/40 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
48.
METHODS FOR DETERMINING RESPONSIVENESS TO CANCER THERAPY
A cell-free DNA fragmentome method (DELFI-TF) is described to evaluate circulating tumor fraction during therapy. DELFI-TF rapidly determined disease progression in patients receiving immunotherapy.
C12Q 1/6874 - Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation [SBH]
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
Compositions include biosensors and enzyme substrates for use in the biosensors. Methods of identifying modulators of enzymatic activity include the biosensors.
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
C12Q 1/48 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving transferase
50.
METHODS FOR PREVENTING OR SLOWING THE PROGRESSION OF COGNITIVE DECLINE OR IMPAIRMENT IN SUBJECTS DISPLAYING NORMAL COGNITIVE PERFORMANCE
Methods for preventing or slowing the progression of cognitive impairment or preventing the development or reducing the rate of cognitive decline in a subject displaying or presenting with cognitive performance within the normal range for the subject's age. The methods comprise administering to the subject one or more of levetiracetam, brivaracetam or seletracetam, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising levetiracetam, brivaracetam or seletracetam or pharmaceutical salt thereof and a pharmaceutically acceptable carrier, a GABAA α5 receptor agonist or a pharmaceutically acceptable salt, hydrate, solvate, isomer, or polymorph thereof, a pharmaceutical composition comprising a GABAA α5 receptor agonist or a pharmaceutically acceptable salt, hydrate, solvate, isomer, or polymorph thereof, and a pharmaceutically acceptable carrier, or a combination or a composition comprising the levetiracetam, brivaracetam or seletracetam or pharmaceutical salt thereof and the GABAA α5 receptor agonist or a pharmaceutically acceptable salt, hydrate, solvate, isomer, or polymorph. In some embodiments, the subjects have one or more risk factors that are predictive for or associated with the development or progression of cognitive impairment or decline.
A61K 31/4015 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
A61K 9/00 - Medicinal preparations characterised by special physical form
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
51.
METHODS AND MATERIALS FOR TREATING SYNGAP1-ASSOCIATED NEURODEVELOPMENTAL DISORDERS
This document provides methods and materials for treating SYNGAP1-associated neurodevelopmental disorders (NDDs; e.g., SYNGAP1-related intellectual disability (SRID)). For example, viral vectors (e.g., adeno-associated viral (AAV) vectors) that include (e.g., are designed to include) nucleic acid encoding a truncated Syngap1 polypeptide (e.g., Syngap1-B:α1 polypeptide) are provided. In some cases, one or more viral vectors provided herein (e.g., AAV vectors that include nucleic acid encoding a truncated Syngap1 polypeptide such as a Syngap1-B:α1 polypeptide) can be administered to a mammal (e.g., a human) having, or at risk for developing, a SYNGAP1-associated NDD (e.g., SRID) to treat the mammal.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
A61P 25/00 - Drugs for disorders of the nervous system
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
52.
METAL/RADIOMETAL-LABELED PSMA INHIBITORS FOR PSMA-TARGETED IMAGING AND RADIOTHERAPY
Low-molecular weight gadolinium (Gd)-based MR contrast agents for PSMA-specific T1-weighted MR imaging are disclosed. The (Gd)-based MR contrast agents exhibit high binding affinity for PSMA and exhibit specific T1 contrast enhancement at PSMA+ cells. The PSMA-targeted Gd-based MR contrast agents can be used for PSMA-targeted imaging in vivo. 86Y-labeled PSMA-binding ureas also are provided, wherein the PSMA-binding ureas also are suitable for use with other radiotherapeutics.
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
53.
ENHANCED FLUORESCENCE SIGNAL THROUGH THE APPLICATION OF AROMATIC ADDITIVES ONTO THE MICROSCOPY SAMPLE FOR STANDARD FLUORESCENCE, FLUORESCENCE MICROSCOPY AND COMBINED FLUORESCENCE MALDI MICROSCOPY/IMAGING
Methods for enhancing a fluorescence intensity of a sample by adding an aromatic compound thereto. Workflows for a combined fluorescence-MALDI microscopy/imaging instrument also are disclosed comprising combining MALDI imaging and fluorescence imaging of the same sample in one sample preparation step. The presently disclosed workflow reduces the sampling time to one workday and minimizes sample degradation.
Compositions comprising one or more targeting (or high affinity) radionuclide-antibody conjugates and one or more non-targeting (or low affinity) radionuclide-antibody conjugates and their use in treating solid tumors are disclosed.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
55.
VENTRICULAR TACHYCARDIA ABLATION SITE IDENTIFICATION
A system for, and method of, identifying an ablation site are presented. The techniques of the method and implemented by the system may include: generating a model of at least one ventricle of a patient; simulating pacing, in the model, where the simulating pacing induces a simulated premature heartbeat in the model; recording an activation time and a repolarization time resulting from the simulating pacing at each of multiple nodes in the model; determining, based on the multiple activation times and repolarization times, a reentry susceptibility quantification at each of multiple nodes in the model; identifying a candidate ablation site based on the multiple reentry susceptibility quantifications; simulating, in the model, an ablation at the candidate ablation site; and determining, using the model, that the simulating the ablation prevents a simulated pacing from inducing simulated reentrant ventricular tachycardia.
Provided herein are nucleic acid vaccine constructs comprising synthetic polynucleotides encoding a Mycobacterium tuberculosis (Mtb) RelA-SpoT homolog (RSH) protein, RelMtb, or a functional portion, fragment, or variant thereof, conjugated to a macrophage inflammatory protein-3 alpha (MIP-3α) or other chemokine that binds to a chemokine receptor 6 (CCR6), or a functional portion, fragment, or variant thereof, or to an antibody, or antigen binding portion thereof, that binds to a CCR6. Methods for making the vaccine constructs and their use in prophylaxis and treatment of Mtb infections are also provided.
A61K 39/04 - Mycobacterium, e.g. Mycobacterium tuberculosis
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61P 31/06 - Antibacterial agents for tuberculosis
Methods of designing, generating, screening, and identifying one or more of these peptides possessing multiple functionalities, for example, including (i) high binding to a cellular target (e.g., melanin pigment in the eye), (ii) high cell-penetration (e.g., to enter cells and access melanin in the melanosomes), and (ii) low cytotoxicity have been developed. Peptides or drug conjugates thereof having these multiple functionalities are particularly effective for selective delivery, prolonged residence, and sustained release of active agents to the epithelial tissues via mucosal surfaces. Methods of using these peptides are also described.
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61K 9/00 - Medicinal preparations characterised by special physical form
THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. (USA)
JOHN HOPKINS UNIVERSITY (USA)
Inventor
Li, Renhua
Elster, Eric, A.
Schobel-Mchugh, Seth, A.
Brandacher, Gerald
Oh, Byoung Chol
Abstract
The present disclosure describes techniques for generating a skin rejection prediction model. The skin rejection prediction model may predict the likelihood of skin rejection for a skin graft site. Tire skin rejection prediction model may be generated by using a plurality of feature selection models to select a model subset from training data. Candidate skin rejection prediction models may be trained using the model subset. The skin rejection prediction model may be selected from the candidate prediction models based on determining a performance metric associated with each candidate prediction using a test subset of tire training data.
G16B 50/30 - Data warehousingComputing architectures
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
59.
Colorimetric Detection of Organic Amines Using Metal-Organic Frameworks
Provided is an article for detecting organic amines, wherein the article includes a solid support impregnated with an indicator reagent comprising a metal-organic framework structure. Also provided is a method of detecting organic amines, wherein the method includes the step of exposing an article comprising a solid support impregnated with an indicator reagent to a medium including an organic amine to produce a color change, wherein the indicator reagent includes a metal-organic framework structure.
G01N 21/78 - Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator producing a change of colour
G01N 31/22 - Investigating or analysing non-biological materials by the use of the chemical methods specified in the subgroupsApparatus specially adapted for such methods using chemical indicators
G01N 33/52 - Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper
G01N 33/94 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving narcotics
This disclosure describes methods of and systems for screening for sepsis or septic shock in a patient and methods of ruling out sepsis or septic shock in a patient using white blood cell count (WBC), a monocyte cell population parameter, or neutrophil-to-lymphocyte ratio (NLR), or a combination thereof, in the blood sample from the patient.
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G01N 27/02 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance
G16H 15/00 - ICT specially adapted for medical reports, e.g. generation or transmission thereof
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
61.
GLUTAMATE AND GLUTAMINE METABOLITES WITH OR WITHOUT dsRNA TO PROMOTE WOUND HEALING
Engineered enzymes for amplification of nucleic acid sequences which function at constant temperatures thereby eliminating heating and cooling cycles associated with traditional polymerase chain reaction (PCR) are disclosed. Specifically, novel, genetically engineered PcrA helicase enzymes are utilized in conjunction with amplification components to provide a method for amplification of nucleic acid sequence by incubating at a substantially isothermal temperature i) a composition comprising a target sequence, ii) primers and iii) said engineered PcrA helicase, a single stranded binding protein (SSB), a polymerase, and/or a thermostable pyrophosphatase (PPase) buffer, or combinations thereof.
C12Q 1/533 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving isomerase
Provided herein is technology relating to treatment of diseases e.g. neurodegenerative diseases caused by repeat-associated non-AUG translation of nucleotide repeat expansions and particularly, but not exclusively, to methods of treating disease by inhibiting DHX36 helicase by administering to the patient an inhibitor of DHX36 in order to provide an effective therapeutic intervention for treating pathogenesis related to the C9orf72 nucleotide repeat expansions.
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
C12Q 1/34 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving hydrolase
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
64.
MACHINE LEARNING DETECTION OF HYPERMETABOLIC CANCER BASED ON NUCLEAR MAGNETIC RESONANCE SPECTRA
A computer-implemented machine learning system for, and method of, detecting a hypermetabolic cancer based on a nuclear magnetic resonance spectrum of a patient biofluid is presented. The techniques includes obtaining a nuclear magnetic resonance spectrum of a patient biofluid; providing the nuclear magnetic resonance spectrum to a machine learning system trained with a training corpus, the training corpus including a group of normal biofluid nuclear magnetic resonance spectra and a group of hypermetabolic cancer biofluid nuclear magnetic resonance spectra; and supplying an indication based on an output of the machine learning system, where the indication is representative of whether the nuclear magnetic resonance spectrum of the patient biofluid is indicative of cancer.
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
65.
CRISPR-Cas9 AS A SELECTIVE AND SPECIFIC CELL KILLING TOOL
A CRISPR-Cas9 system for treating a disease, disorder, or condition associated with one or more somatic mutations in a subject in need of treatment thereof is disclosed. The system comprises a sgRNA-guided Cas9, wherein the sgRNA targets between about 1 to about 50 mutations in a target cell. The CRISPR-Cas9 system can be used to treat diseases, disorders, or conditions associated with one or more somatic mutations, including cancers, autoimmune diseases, and/or neurodegenerative diseases. Additionally, the present disclosure relates to methods of identifying somatic mutations in a tumor that produce a protospacer adjacent motif (PAM) and methods of designing a CRISPR-Cas 9 system to target PAMs identified in a tumor sample obtained from a subject.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
The present disclosure generally relates to methods of diagnosing and/or treating dysautonomia associated disorders, as well as methods of predicting responsiveness of subjects suffering from or suspected of having dysautonomia associated disorders to certain treatments.
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
C12Q 1/6827 - Hybridisation assays for detection of mutation or polymorphism
A61P 25/00 - Drugs for disorders of the nervous system
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
67.
NEXT GENERATION DESIGNER LIVER ORGANOIDS AND THEIR METHODS OF PREPARATION AND USE
ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (USA)
The Johns Hopkins University (USA)
Inventor
Kiani, Samira
Ebrahimkhani, Mo R.
Velazquez, Jeremy
Legraw, Ryan
Cahan, Patrick
Abstract
The present disclosure relates to synthetic liver organoids and methods of using such synthetic liver organoids for various applications including drug discovery and modeling human liver development. In particular, provided herein are methods of producing and using synthetic mature liver organoids comprising mature, functional cells found in the human liver.
Techniques for using neural data to perform an action are presented. The techniques can include: receiving first digitized neural data representing first neural sensor data; passing the first digitized neural data to a first trained machine learning system, where the first trained machine learning system outputs a selection indication; selecting, based on the selection indication, a second trained machine learning system and an application; receiving second digitized neural data representing second neural sensor data; passing the second digitized neural data to the second trained machine learning system, where the second trained machine learning system outputs a control indication; and passing the control indication to the application, where the application performs an action based on the control indication.
G06F 3/01 - Input arrangements or combined input and output arrangements for interaction between user and computer
A61B 5/24 - Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
A61F 4/00 - Methods or devices enabling patients or disabled persons to operate an apparatus or a device not forming part of the body
G16H 40/60 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
69.
NON-VIRAL NANOPARTICLE FORMULATIONS FOR OCULAR GENE DELIVERY
Methods for treating a disease or condition of an eye comprising administering to the suprachoroidal space of the eye a particle composition comprising a poly(beta-amino ester) (PBAE) polymer, DNA comprising at least one gene of interest, wherein the polymer to the DNA has a mass ratio between about 10:1 to about 50:1.
C08G 69/26 - Polyamides derived from amino carboxylic acids or from polyamines and polycarboxylic acids derived from polyamines and polycarboxylic acids
C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
A dendrimer formulation, such as a PAMAM dendrimer or a multiarm PEG polymeric formulation has been developed for systemic administration to the brain or central nervous system. In the preferred embodiment, the dendrimers are in the form of dendrimer nanoparticles comprising poly(amidoamine)(PAMAM) hydroxyl-terminated dendrimers covalently linked to at least one therapeutic, prophylactic or diagnostic agent for treatment of one or more symptoms of neurodegenerative, neurodevelopmental or neurological disorders such as Rett syndrome of autism spectrum disorders. D6 generation dendrimers provide significantly enhanced uptake into areas of brain injury, providing a means for diagnosis as well as drug delivery.
A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
A61K 47/59 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
A standardized, sterile device for leg support during orthopaedic surgery, is described herein. The leg support device of the present invention will serve to create a sterile, efficient, easily replicable set up for ankle arthroscopy. The device of the present invention includes a wedge that defines a central recess configured to receive a leg of the patient. The height and size of the device can be customizable to accommodate positioning for ankle arthroscopy procedures regardless of patient size or weight. The device can, in some embodiments, include a sterile sleeve configured to fit the device. The sterile sleeve further allows for easy manipulation of the device during the procedure.
A system for controlling an additive manufacturing processing may include an energy source operable to emit a beam to heat a powder bed to form a melt pool, a detection system disposed for on axis sensing of a temperature profile of the melt pool where the detection system includes a plurality of independently filtered channels that each monitor a spectral response of the melt pool to determine the temperature profile based on the spectral response of the plurality of independently filtered channels, and a control system comprising a high speed FPGA or ASIC operably coupled to the detection system to receive the temperature profile and define a control response for controlling operation of the energy source.
Techniques for wirelessly providing Global Positioning System (GPS) data from a vehicle to an entity are presented. The techniques include: obtaining, from a GPS receiver, GPS data for the vehicle, where the GPS data includes data representing at least a latitude of the vehicle and a longitude of the vehicle; generating a packet representing the GPS data, where the packet includes: a latitude data field including latitude data, a field including data representing a length of the latitude data field, a longitude data field including longitude data, and a field including data representing a length of the longitude data field, where the latitude data field and the longitude data field are variable in length among different packets; and sending, wirelessly, the packet to the entity.
G01S 19/09 - Cooperating elementsInteraction or communication between different cooperating elements or between cooperating elements and receivers providing processing capability normally carried out by the receiver
G01S 19/01 - Satellite radio beacon positioning systems transmitting time-stamped messages, e.g. GPS [Global Positioning System], GLONASS [Global Orbiting Navigation Satellite System] or GALILEO
H03M 7/30 - CompressionExpansionSuppression of unnecessary data, e.g. redundancy reduction
G08G 1/123 - Traffic control systems for road vehicles indicating the position of vehicles, e.g. scheduled vehicles
Dendrimer-drug compositions have been developed that not only target the reactive inflammatory cells/macrophages in the plaque, but also in the adipose tissue, delivering drugs in a targeted manner to simultaneously and independently address both atherosclerosis and obesity, and associated metabolic disorders. The dendrimers are preferably glucose dendrimers, hydroxyl-terminated PAMAM dendrimers, or sugar-modified dendrimers, most preferably glucose dendrimers. The drugs are preferably a PPAR-α agonist; a PPAR-γ agonist; a dual PPAR agonist (e.g., a PPAR- α/γ agonists); a GLP-1 receptor agonist (e.g., semaglutide); a metformin; an SGLT2 agonist, a GIP-1 receptor agonist or antagonist; a dual GLP-1/GIP-1 receptor agonist (e.g., tirzepatide); a mitochondrial uncoupler (e.g., niclosamide); or a combination thereof. These compositions have the ability to overcome the side effects of current drugs for obesity and heart disease, and open new avenues in addressing these disorders through targeting of selective cells.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 47/59 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
75.
SHORT VIRAL RNAS (SVRNAS) WITH THERAGNOSTIC POTENTIAL IN INFECTION WITH SARS-COV-2 AND RELATED VIRUSES
Provided herein are short viral RNA (svRNA) and human RNA sequences that exhibit modulated expression during viral infection and are therefore useful for detecting viral infections. Further disclosed herein are compositions, methods, and kits for detecting and treating infections, including early-stage and latent infections with low viral titers. In certain embodiments the compositions, methods, and kits for detecting and treating infections include detecting in a sample from a subject 10-50 nucleotide length short viral RNA (svRNA), modulated expression of 10-50 nucleotide length RNA in the subject, or a combination thereof, thereby detecting infection by a virus in the subject.
Methods, systems, and computer programs for treating cancer are disclosed. In one aspect, the method includes obtaining data that represents one or more genomic variants, for each genomic variant: determining a candidate RNA sequence guide based on the genomic variant, determining feature data based on the candidate RNA sequence guide, encoding the extracted feature data into a data structure, providing the encoded data structure as an input to a machine learning model, processing the encoded data structure through each of the layers of the trained machine learning model to generate output data indicating a probability of on-target cleavage and a probability of off-target cleavage for the candidate RNA sequence guide that corresponds to the encoded data structure, obtaining output data generated by the machine learning model based on the machine learning processing the encoded data structure, and determining one or more cleavage sites based on the obtained output data.
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
77.
PROSTATE-SPECIFIC MEMBRANE ANTIGEN TARGETED HIGH-AFFINITY AGENTS FOR ENDORADIOTHERAPY OF PROSTATE CANCER
C07D 257/02 - Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
78.
SYSTEM FOR MONITORING OF THE FUNCTIONAL STATUS OF IMPLANTED HEART VALVES
The present invention is directed to a system for monitoring the functional status of an implantable heart valve. The system includes wireless pressure sensors that are embedded in the implantable heart valve. An external device receives signal transmitted from the wireless pressure sensors. The external device reads and analyzes these signals and then transmits the data to a healthcare provider.
We queried DNA from saliva or plasma of 93 HNSCC patients, searching for somatic mutations or human papillomavirus genes, collectively referred to as tumor DNA. When both plasma and saliva were tested, tumor DNA was detected in 96% (95% CI, 84% to 99%) of 47 patients. The fractions of patients with detectable tumor DNA in early-and late-stage disease were 100% (n=10) and 95% (n=37), respectively. Saliva is preferentially enriched for tumor DNA from the oral cavity, whereas plasma is preferentially enriched for tumor DNA from the other sites. Tumor DNA in the saliva and plasma is a valuable biomarker for detection of HNSCC.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
An optical module for spatially offset Raman spectroscopy, the optical module comprising: a laser source mounted on a substrate and configured to emit electromagnetic radiation at a target; a plurality of sensors mounted on the substrate and configured to detect electromagnetic radiation scattered from a plurality of depths in the target; and a first plurality of filters, each disposed over one or more of the plurality of sensors, wherein, the plurality of sensors and filters are arranged on the substrate at spatially offset positions from the laser source; and wherein the first plurality of filters are substantially transparent to a first wavelength band corresponding to a Raman scattering wavelength of a first molecule of the target and substantially opaque to wavelengths outside the first wavelength band.
Glucose dendrimers synthesized using a hypercore and glucose monosaccharide-based branching units significantly enhances accumulation in neurons in the brain and in retina when administered in vivo, as compared with dendrimers without glucose monosaccharide-based branching units such as PAMAM. Compositions of glucose dendrimers conjugated with one or more therapeutic, prophylactic or diagnostic agents to prevent, treat, or diagnose a disease or disorder in a subject in need thereof, and methods of use thereof, have been developed. The compositions are particularly suited for treating and/or ameliorating diseases or disorders associated with diseased neurons in the eye or the brain. Methods of treating a human subject having or at risk of a neurological disease or disorder are provided.
A61K 47/61 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
An embodiment in accordance with the present invention provides a new biopsy needle that may address several problems identified with currently available biopsy needles. In short, the new needle has a straighter insertion path, no forward fire, lower noise, and is pneumatic power-assisted so that it can be operated with one hand. These features improve biopsy targeting, provide safer operation for the patient and personnel, reduce patient discomfort, and respectively make optional the help of an assistant at biopsy.
The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (USA)
The Johns Hopkins University (USA)
Inventor
Brody, David L.
Blodgett, David
Cohen, Adam
Rodriguez, Carissa
Sleasman, Timothy
Fitch, Michael J.
Abstract
An intracranial access device includes a housing having an operator-facing side and a patient-facing side and an opening therethrough extending from the operator-facing side to the patient-facing side. The device further includes at least one fastener configured to secure the device to a cranium of a patient. The device further includes a drill mounted to a surface of the housing and a cauterizer. The device may further include a number of sensors arranged on the patient-facing side of the housing and configured to identify a hemorrhage location.
A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
A61B 90/10 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges for stereotaxic surgery, e.g. frame-based stereotaxis
A61B 90/11 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges for stereotaxic surgery, e.g. frame-based stereotaxis with guides for needles or instruments, e.g. arcuate slides or ball joints
A61N 1/05 - Electrodes for implantation or insertion into the body, e.g. heart electrode
Disclosed is a method for producing an ordered graphitic carbon. Said method includes contacting a material including disordered elemental carbon and a metal with chlorine gas, thereby yielding a gaseous product comprising a chloride of the metal and a solid product comprising the ordered graphitic carbon. A lithium ion battery comprising the ordered graphitic carbon.
A computer implemented method, system, and non-transitory computer-readable device for implementing a generalized metadata generation system for omics data is provided. In some embodiments, a generalized reconstruction model may be trained to perform anomaly detection on an unlabeled omics feature vector. Various embodiments provide generalized anomaly detection that are agnostic to specific organs or exposure groups through aggregating and preprocessing omics data from disparate datasets. The generalized metadata generation system may then generate and assign an anomalous or non-anomalous label as metadata to improve computational interpretability of omics data.
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
86.
METHOD AND SYSTEM FOR DELIVERY OF THERAPEUTICS TO EYE
A surgical instrument is provided for delivery of therapeutic agents into an eye. The instrument includes a cannula that is connected to a handle of the instrument and through which therapeutic agents are delivered into the eye via a continuous and controlled infusion. In certain aspects, a sheath which has a diameter greater than that of the cannula accommodates the cannula therein. An insertion tip is formed at a distal end of the cannula to penetrate tissue of the eye at a tangential angle.
A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
Producing an ordered graphitic carbon includes contacting a material including disordered elemental carbon and a metal with chlorine gas, thereby yielding a gaseous product comprising a chloride of the metal and a solid product comprising the ordered graphitic carbon.
Imaging and radiotherapeutics agents targeting fibroblast-activation protein-α (FAP-α) and their use in imaging and treating FAP-α related diseases and disorders are disclosed.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
89.
EFFICIENT LIQUID-AIR CONTACTOR IN PARALLEL FLOW CONFIGURATION
The present invention is in the field of carbon dioxide capture, in particular the capture of carbon dioxide directly from air or some other emission source. The invention concerns a device and a process for the capture of carbon dioxide, from air or some other emission source, using hydroxide solutions as the sorbent.
B01D 53/14 - Separation of gases or vapoursRecovering vapours of volatile solvents from gasesChemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by absorption
B01D 53/22 - Separation of gases or vapoursRecovering vapours of volatile solvents from gasesChemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by diffusion
B01D 69/02 - Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or propertiesManufacturing processes specially adapted therefor characterised by their properties
The present disclosure relates to multi-principal element alloy (MPEA) nanoparticles and the synthesis of said MPEA nanoparticles in organic solutions. The present disclosure also relates to catalysts comprising the MPEA nanoparticles for use, for example, in fuel cells and water electrolyzers.
B22F 9/24 - Making metallic powder or suspensions thereofApparatus or devices specially adapted therefor using chemical processes with reduction of metal compounds starting from liquid metal compounds, e.g. solutions
C22C 5/04 - Alloys based on a platinum group metal
C25B 11/081 - Electrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of a single catalytic element or catalytic compound the element being a noble metal
Techniques for natural language control of an imaging device are presented. The techniques use an imaging device interface, a language model interface, an audio interface, and a human model. The audio interface receives an audio input from a user, transcribes the audio input, and provides the audio input transcription to the language model interface. The language model interface provides the audio input transcription to the language model, receives a response from the language model, and provides the response to the human model. The human model maintains a representation of a current position of an individual, receives the response from the language model interface, forms an action request based on the response and the current position of the individual, and sends the action request to imaging device interface. The imaging device interface sends the action request to the imaging device, such that the imaging device acts on the action request.
This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt thereof, or an N-oxide thereof) of formula (I), which are positive allosteric modulators of one or more GABA-A receptors, e.g., which are peripherally restricted, positive allosteric modulators of one or more GABA-A receptors; e.g., which are positive allosteric modulators of one or more GABA-A receptors and which selectively target the peripheral nervous system and organs of the body, and which do not substantially pass through the blood-brain barrier. Said compounds are useful e.g., for the treatment of systemic diseases of the body, e.g., diseases in which modulation of one or more peripherally restricted GABA-A receptors is beneficial (e.g., diseases or disorders which are mediated by GABA-A neuronal activitye. This disclosure also features pharmaceutical compositions containing the chemical entities described herein as well as methods of using same for the treatment of systemic diseases of the body.
This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt thereof, or an N-oxide thereof) of formula (I), which are positive allosteric modulators of one or more GABA-A receptors, e.g., which are peripherally restricted, positive allosteric modulators of one or more GABA-A receptors; e.g., which are positive allosteric modulators of one or more GABA-A receptors and which selectively target the peripheral nervous system and organs of the body, and which do not substantially pass through the blood-brain barrier. Said compounds are useful e.g., for the treatment of systemic diseases of the body, e.g., diseases in which modulation of one or more peripherally restricted GABA-A receptors is beneficial (e.g., diseases or disorders which are mediated by GABA-A neuronal activitye. This disclosure also features pharmaceutical compositions containing the chemical entities described herein as well as methods of using same for the treatment of systemic diseases of the body.
Improved hypotonic gelling vehicles are described as solubilizing agents for drugs and as a means to provide sustained drug delivery to the eye. It has been discovered that the addition of small amounts of low molecular weight PEG to hypotonic gel-forming compositions enhances the viscosity of the solution at the ocular surface, prologs tear break-up time and increases ocular comfort. Solubilizing drugs at higher concentrations enhances drug penetration into the tissues of the body, while the hypotonic gelling vehicle further improves distribution of the drug over a larger surface area for increased absorption and sustained release for reduced side effects and longer duration of action.
According to various embodiments, a system for, and method of, presenting olfactory stimuli for olfactory dysfunction testing and training is disclosed. The system includes an integrated device. The integrated device includes: a plurality of scent chambers, where each scent chamber includes a respective material having a corresponding scent, such that the plurality of scent chambers include a plurality of different materials having a corresponding plurality of different scents. The integrated device is operable to selectively expose an aperture of an individual scent chamber, such that a corresponding scent of a corresponding material in the individual scent chamber is exposed for sampling by a user.
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
G16H 50/80 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for detecting, monitoring or modelling epidemics or pandemics, e.g. flu
A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
A61K 31/662 - Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
C07C 259/06 - Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
C07J 9/00 - Normal steroids containing carbon, hydrogen, halogen, or oxygen, substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
C07J 41/00 - Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
A61P 1/06 - Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
96.
MIR-211 AND ACSL4 AS THERAPEUTIC AGENTS FOR CHILDHOOD CANCER MEDULLOBLASTOMAS
UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC (USA)
Inventor
Perera, Ranjan J.
Rangaramanujam, Kannan
Hanes, Justin
Seal, Sudipta
Abstract
Nanoparticles comprising miR-211 and their use for treating brain cancers, such as medulloblastomas, including pediatric medulloblastomas, are disclosed.
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
Prostate-specific membrane antigen (PSMA) binding compounds having radioisotope substituents are described, as well as chemical precursors thereof. Compounds include pyridine containing compounds, compounds having phenylhydrazine structures, and acylated lysine compounds. The compounds allow ready incorporation of radionuclides for single photon emission computed tomography (SPECT) and positron emission tomography (PET) for imaging, for example, prostate cancer cells and angiogenesis.
A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
C07C 275/16 - Derivatives of urea, i.e. compounds containing any of the groups the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton being further substituted by carboxyl groups
C07C 275/18 - Derivatives of urea, i.e. compounds containing any of the groups the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
A polymer having the structure N+ Ar is a N-containing monocyclic or bicyclic aromatic ring having 1 or 2 N atoms, at least one of the N atoms is substituted with Ra to have a positive charge and the ring is optionally substituted with Rb, Ra is H, thiophene, furan, pyridine, benzene, thiazole, C1-C12 alkyl optionally substituted with one or more F atoms, or polyoxyethylene (—(CH2CH2O)n—H and Rb is H, C1-C12 alkyl, aralkyl, or C1-C12 alkoxy. Ar is a phenyl or naphthalene ring, optionally substituted with Rc or CO2Ph. Any of the phenyl or naphthalene rings is substituted with Rc which is H, C1-C12 alkyl, or C1-C12 alkoxy, and Rd is H or Me. X is halogen, bicarbonate (HCO3−), carbonate, bisulfate (HSO4−), bisulfite (HSO3−), methane sulfonate (MeSO3−). triethyl borohydride (Et3BH−) or a C1-C6 carboxylate. The ratio of x:y is from about 99:1 to about 1:99.
C08L 65/00 - Compositions of macromolecular compounds obtained by reactions forming a carbon-to-carbon link in the main chainCompositions of derivatives of such polymers
H10K 10/46 - Field-effect transistors, e.g. organic thin-film transistors [OTFT]
A system for pacing a heart of a patient includes a wire having a first end and a second end. The first end is configured to be connected to a pulse generator. The second end includes one or more connectors. The system also includes one or more anchors that are configured to be attached to the heart of the patient. The one or more connectors are configured to be releasably connected to the one or more anchors. The pulse generator is configured to transmit electrical pulses through the wire and the one or more connectors to the heart to pace the heart after a cardiac surgery.
Small molecule radiohalogenated PSMA inhibitors and metal complexes thereof and their use in radioimaging and radiotherapy for treating PSMA-related diseases, including prostate cancer, are disclosed. The combination of small molecule radiohalogenated PSMA inhibitors with a competitive PSMA ligand for reducing off-target accumulation of the radiohalogenated PSMA inhibitor also is disclosed.
